目的采用固体分散技术将水飞蓟素制成滴丸,以增加其溶出速度,提高生物利用度。以星点设计-效应面优化法对制备工艺进行优化,筛选最佳处方。方法以Po loxam er 188的用量及药物的质量分数为考察因素,崩散时间以及一定时间的溶出度为指标,采用多元线性回归及二次和三次多项式拟合建立指标与考察因素之间的数学关系,根据最佳数学模型描绘效应面,再根据效应面优选最佳条件。结果三次多项式是描述指标与因素之间的最佳模型,r=0.998。最佳处方滴丸的崩散时间及溶出度的理论预测值与实测值偏差较小,模型具有良好的预测性。60 m in溶出度为普通片剂的19倍。结论水飞蓟素制成滴丸后溶出速度显著提高,星点设计-效应面优化法可以很好地应用于处方筛选。
Ahn To develop a high resolution HPLC method for the determination of ondansetron in human plasma and to study the pharmacokinetics of ondansetron in orally disintegrating tablets. Methods HPLC determination involved liquid-liquid extraction, separation on a CN column and ultraviolet detection at 310 ran with granisetron as an internal standard. Pharmacokinetics and bioequivalence of ondansetron in orally disintegrating tablets by direct compression and conventional 8 mg tablets were evaluated and compared in 20 healthy human male volunteers after a single oral dose in a randomized cross-over study. Results The limit of quantification was 0.25 ng· mL^-1. The recovery was about 85 % or over for ondan setron and about 90% for internal standard. Linearity was good within the concentration range of 0.5 - 50 ng·mL^-1 with r^2 ranging from 0.997 1 to 0.999 9. Intra- and inter-assay coefficients of variation ranged from 1.78% to 2.38% and 3.88% -5.19%, respectively. Accuracies for spiked concentrations of 2.0, 10.0, and 30.0 ng·mL^-1 were 104.7% ±4.4%, 102.2% ± 1.1%, and99.51% ±2.34%, respectively. Pharmacokinetic parameters of AUCo-t, AUCo-∞ , Cmax, Tmax, and T1/2 were 230.2 ± 78.0 ng·h·L^-1 , 265.2± 101.5 ng·h·mL^-1, 35.67 ± 8.94 ng·mL^-l, 1.51 ±0.79 h, and 5.00± 1.41 h for orally disintegrating tablets, respectively. The analysis of variance did not show any significant difference between orally disintegrating tablets and conventional tablets, and 90% confidence intervals fell within the acceptable range for bioequivalence. Conclusion High resolution HPLC method has been set up and applied in pharmacokinetic evaluation of ondansetron in orally disintegrating tablets.
